Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
Authors:
- Brigitte C. WidemannBWBrigitte C. Widemann
- Eva DombiEDEva Dombi
- Andrea GillespieAGAndrea Gillespie
- Pamela L. WoltersPWPamela L. Wolters
- Jean BelascoJBJean Belasco
- Stewart GoldmanSGStewart Goldman
- Bruce R. KorfBKBruce R. Korf
- Jeffrey SolomonJSJeffrey Solomon
- Staci MartinSMStaci Martin
- Wanda SalzerWSWanda Salzer
- Elizabeth FoxEFElizabeth Fox
- Nicholas PatronasNPNicholas Patronas
Open Access
- 4 February 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 16 (5) , 707-718
Abstract
RAS is dysregulated in neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PNs). The activity of tipifarnib, which blocks RAS signaling by inhibiting its farnesylation, was tested in children and young adults with NF1 and progressive PNs. Patients aged 3–25 years with NF1-related PNs and imaging evidence of tumor progression were randomized in a double-blinded fashion to receive tipifarnib (200 mg/m2 orally every 12 h) or placebo (phase A) and crossed over to the opposite treatment arm at the time of tumor progression (phase B). PN volumes were measured with MRI, and progression was defined as ≥20% volume increase. Time to progression (TTP) in phase A was the primary endpoint, and the trial was powered to detect whether tipifarnib doubled TTP compared with placebo. Toxicity, response, and quality of life were also monitored. Sixty-two patients were enrolled. Tipifarnib and placebo were well tolerated. On phase A, the median TTP was 10.6 months on the placebo arm and 19.2 months on the tipifarnib arm (P = .12; 1-sided). Quality of life improved significantly compared with baseline on the tipifarnib arm but not on the placebo arm. Volumetric tumor measurement detected tumor progression earlier than conventional 2-dimensional (WHO) and 1-dimensional (RECIST) methods. Tipifarnib was well tolerated but did not significantly prolong TTP of PNs compared with placebo. The randomized, flexible crossover design and volumetric PN assessment provided a feasible and efficient means of assessing the efficacy of tipifarnib. The placebo arm serves as an historical control group for phase 2 single-arm trials directed at progressive PNs.Keywords
This publication has 42 references indexed in Scilit:
- Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1The Journal of Pediatrics, 2012
- Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromasNeurology, 2011
- Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromasNeurology, 2009
- Health‐related quality of life measures in genetic disorders: An outcome variable for consideration in clinical trialsAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2009
- Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform NeurofibromasPediatric Neurology, 2007
- Guidelines for the diagnosis and management of individuals with neurofibromatosis 1Journal of Medical Genetics, 2006
- Protein farnesylation: Implications for normal physiology, malignant transformation, and cancer therapyCancer Cell, 2005
- Proteomic Analysis Reveals Hyperactivation of the Mammalian Target of Rapamycin Pathway in Neurofibromatosis 1–Associated Human and Mouse Brain TumorsCancer Research, 2005
- Incorporating the Patient's Perspective into Drug Development and Communication: An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001Value in Health, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000